215 related articles for article (PubMed ID: 33453149)
21. Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.
Krause PR; Gruber MF
N Engl J Med; 2020 Nov; 383(19):e107. PubMed ID: 33064383
[No Abstract] [Full Text] [Related]
22. Use of the conditional marketing authorization pathway for oncology medicines in Europe.
Hoekman J; Boon WP; Bouvy JC; Ebbers HC; de Jong JP; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):534-41. PubMed ID: 26080745
[TBL] [Abstract][Full Text] [Related]
23. Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.
Joffe S
JAMA; 2021 Jan; 325(3):221-222. PubMed ID: 33315069
[No Abstract] [Full Text] [Related]
24. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
Vassal G; de Rojas T; Pearson ADJ
Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
[TBL] [Abstract][Full Text] [Related]
25. The system of mutual recognition of batch release in the EU--implications for combined vaccines.
Dobbelaer R
Biologicals; 1994 Dec; 22(4):377-80. PubMed ID: 7779364
[No Abstract] [Full Text] [Related]
26. The US Regulatory System and COVID-19 Vaccines: The Importance of a Strong and Capable FDA.
Sharfstein JM; Goodman JL; Borio L
JAMA; 2021 Mar; 325(12):1153-1154. PubMed ID: 33587124
[No Abstract] [Full Text] [Related]
27. Rolling Reviews During COVID-19: The European Union Experience in a Global Context.
Marinus R; Mofid S; Mpandzou M; Kühler TC
Clin Ther; 2022 Mar; 44(3):352-363. PubMed ID: 35123802
[TBL] [Abstract][Full Text] [Related]
28. Emergency Use Authorization of COVID-19 Vaccine: Implications for Worker Communities.
Culp K; Dukes KC; Cowin C; Sinnwell E
Workplace Health Saf; 2021 Apr; 69(4):152-153. PubMed ID: 33787400
[No Abstract] [Full Text] [Related]
29. The European Medicines Agency's plans for sharing data from clinical trials.
Groves T; Godlee F
BMJ; 2013 May; 346():f2961. PubMed ID: 23657192
[No Abstract] [Full Text] [Related]
30. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
Nettesheim M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
[TBL] [Abstract][Full Text] [Related]
31. Emergency use authorization (EUA), conditional marketing authorization (CMA), and the precautionary principle at the time of COVID-19 pandemic.
Roncati L; Roncati M
J Public Health Policy; 2021 Sep; 42(3):518-521. PubMed ID: 34316006
[No Abstract] [Full Text] [Related]
32. Transforming vaccine development.
Black S; Bloom DE; Kaslow DC; Pecetta S; Rappuoli R
Semin Immunol; 2020 Aug; 50():101413. PubMed ID: 33127296
[TBL] [Abstract][Full Text] [Related]
33. EU's Ordering of COVID-19 Vaccine Doses: Political Decision-Making under Uncertainty.
Gleißner W; Follert F; Daumann F; Leibbrand F
Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33672157
[TBL] [Abstract][Full Text] [Related]
34. Talk to Patients About: Vaccine Testing.
Price S
Tex Med; 2020 Nov; 116(11):23. PubMed ID: 33641134
[TBL] [Abstract][Full Text] [Related]
35. Why emergency COVID-vaccine approvals pose a dilemma for scientists.
Cyranoski D
Nature; 2020 Dec; 588(7836):18-19. PubMed ID: 33230275
[No Abstract] [Full Text] [Related]
36. WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19.
Saudi Med J; 2021 Apr; 42(4):463-464. PubMed ID: 33795510
[No Abstract] [Full Text] [Related]
37. [The Medical Products Agency's preparations prior to the new EU regulation on children and drugs].
Johannesson M; Berglund EG
Lakartidningen; 2007 Jul 11-24; 104(28-29):2099. PubMed ID: 17702388
[No Abstract] [Full Text] [Related]
38. COVID-19 Vaccine Roundup.
Am J Nurs; 2021 Nov; 121(11):16. PubMed ID: 34673683
[No Abstract] [Full Text] [Related]
39. EU marketing authorization review of orphan and non-orphan drugs does not differ.
Putzeist M; Mantel-Teeuwisse AK; Llinares J; Gispen-De Wied CC; Hoes AW; Leufkens HG
Drug Discov Today; 2013 Oct; 18(19-20):1001-6. PubMed ID: 23835230
[TBL] [Abstract][Full Text] [Related]
40. Approvals of drugs with uncertain benefit-risk profiles in Europe.
Banzi R; Gerardi C; Bertele' V; Garattini S
Eur J Intern Med; 2015 Oct; 26(8):572-84. PubMed ID: 26342723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
